• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Questions Arise Over Political Involvement in Drug Approval Decisions - 2005 News in Review: Important Changes for the Pharmaceutical Industry

Posted on: Monday, 13 March 2006, 09:01 CST

Research and Markets

(http://www.researchandmarkets.com/reports/c32122) has announced the addition of 2005 News in Review: Important Changes for the Pharmaceutical Industry to their offering.

This Decision Resources report casts a look back at 2005 and reviews key events and issues in the news that have had a major impact on the pharmaceutical industry or will help shape the industry in the years to come. The report covers ten important news stories:

-- The Vioxx withdrawal.

-- The Tysabri withdrawal.

-- The approval of BiDil for African-Americans.

-- Medicare Part D.

-- The drug reimportation debate.

-- Controversy about political involvement in the drug approval process.

-- Concerns about a flu pandemic.

-- EU Pharmaceutical Review.

-- Reference pricing for statins in Germany.

-- Increased consolidation in Japan.

-- A Year of Change

-- Vioxx Withdrawal Prompts FDA Reform and Legal Battles

-- Biogen Idec and Elan Withdraw Tysabri

-- FDA Approves BiDil for African-American Patients

-- Medicare Part D: Final Regulations Released and Enrollment Begins

-- Debate Continues on Drug Reimportation

-- Questions Arise Over Political Involvement in Drug Approval Decisions

-- Concerns About a Flu Pandemic Increase

-- EU Pharmaceutical Review Is Incorporated in EU Member States

-- Reference Pricing for Statins Begins in Germany

-- Merger Activity in Japan Increases

Companies mentioned in this report include:

-- Biogen Idec

-- Elan

-- Merck

-- Pfizer

-- GlaxoSmithKline

-- Tanabe

-- Antisense Therapeutics

-- NitroMed

-- Medco Research/King Pharmaceuticals R&D

-- AstraZeneca

-- Barr Pharmaceuticals

-- Sandoz

-- Endo Labs

-- Forest Laboratories

-- Roche

-- Alnylam Pharmaceuticals

-- MedImmune

-- Yamanouchi/Fujisawa

-- Astellas

-- Takeda

-- Sankyo Pharmaceuticals/Daiichi Pharmaceuticals

-- Daiichi-Sankyo

-- Sumitomo Pharmaceuticals/Dainippon Pharmaceuticals

-- Dainippon Sumitomo

-- Novartis

For more information visit http://www.researchandmarkets.com/reports/c32122 Decision Resources

Source: Business Wire

More News in this Category